Acumen Pharmaceuticals (NASDAQ: ABOS) insider files to sell 1,687 shares

Rhea-AI Filing Summary

Acumen Pharmaceuticals insider plans additional stock sale. A person identified as Matt Zuga filed a notice to sell 1,687 shares of Acumen Pharmaceuticals, Inc. common stock through Merrill Lynch on NASDAQ, with an aggregate market value of $3,137.82. These shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, with payment recorded on the same date.

The filing also lists prior sales of Acumen common stock by the same seller over the past three months, including 4,000 shares sold on 01/05/2026, 5,100 shares on 01/06/2026, 5,805 shares on 01/07/2026, 6,888 shares on 01/08/2026, and 2,473 shares on 01/21/2026, each with stated gross proceeds. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the company’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	1687	3137.82	60573425	01/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/17/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			1687	01/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/05/2026	4000	7842.33
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/06/2026	5100	10027.50
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/07/2026	5805	11565.85
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/08/2026	6888	12513.07
Matt Zuga 1210-1220 WASHINGTON STREET SUITE 210 NEWTON MA 02465	Common stock	01/21/2026	2473	4469.18

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Acumen Pharmaceuticals (ABOS) disclose?

The filing discloses that a person named Matt Zuga intends to sell 1,687 shares of Acumen Pharmaceuticals, Inc. common stock through Merrill Lynch on NASDAQ, with an aggregate market value of $3,137.82. It also lists several prior stock sales by the same seller over the past three months.

How many Acumen Pharmaceuticals (ABOS) shares are planned to be sold under this Form 144?

The notice states that 1,687 shares of Acumen Pharmaceuticals, Inc. common stock are to be sold. The planned sale is routed through Merrill Lynch and is tied to an approximate market value of $3,137.82.

How were the 1,687 Acumen Pharmaceuticals (ABOS) shares being sold acquired?

The 1,687 shares were acquired on 01/17/2026 through the vesting of a restricted stock unit award, granted as part of the issuer’s equity compensation plan. The date of payment is also listed as 01/17/2026.

What prior sales by the insider are listed in the Acumen Pharmaceuticals (ABOS) Form 144?

Over the past three months, the filing lists sales by Matt Zuga of Acumen common stock in multiple transactions: 4,000 shares on 01/05/2026, 5,100 shares on 01/06/2026, 5,805 shares on 01/07/2026, 6,888 shares on 01/08/2026, and 2,473 shares on 01/21/2026, each with stated gross proceeds.

On which exchange are the Acumen Pharmaceuticals (ABOS) shares in this Form 144 expected to be sold?

The filing states that the common stock covered by the notice is to be sold on the NASDAQ stock market, with Merrill Lynch listed as the broker.

What representation does the seller make in this Acumen Pharmaceuticals (ABOS) Form 144?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information regarding the current and prospective operations of Acumen Pharmaceuticals, Inc. that has not been publicly disclosed.